DIR Technologies Announces Trial with Pfizer for Integrity Inspection System - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

DIR Technologies Announces Trial with Pfizer for Integrity Inspection System

DIR Technologies reported that Pfizer will perform a three-month trial of the company's packaging integrity testing systems based on thermal imaging. DIR technologies will install a 100% inspection system for exploration of the technology, to potentially replace destructive seal integrity testing across a number of packaging operations to evaluate speed, accuracy, and cost.

The Induction Integrity Verification System is testing in-line the integrity of the aluminum foil sealing of induction-sealed bottles. It is the first system capable of inspecting 100% of the bottles undergoing induction sealing, without resulting in production slowdown and providing continuous process verification. The inspection is done through the cap by means of high sensitivity thermal imaging. The system was launched by DIR Technologies at PACK EXPO in Las Vegas in September 2013.

Source: DIR Technologies


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here